期刊
CANCER LETTERS
卷 521, 期 -, 页码 88-97出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2021.08.034
关键词
Prostate cancer (PCa); SUMOs; SUMOylation; Therapeutic intervention
类别
资金
- National Natural Science Foundation of China [81630075]
- China's National Key RD Programme [2019YFE0110600]
- Shanghai Jinshan World Foreign Language School (Shanghai) [201508]
Protein modification with SUMOs has dual roles in prostate cancer tumorigenesis and development, with deregulated SUMOylation affecting the balance between tumorigenic potential and anticancer effects. SUMOylation on the androgen receptor and oncoproteins plays a role in this pathological process in PCa.
Protein modification with small ubiquitin-like modifiers (SUMOs) plays dual roles in prostate cancer (PCa) tumorigenesis and development. Any intermediary of the SUMO conjugation cycle going awry may forfeit the balance between tumorigenic potential and anticancer effects. Deregulated SUMOylation on the androgen receptor and oncoproteins also takes part in this pathological process, as exemplified by STAT3/NF-kappa B and tumor suppressors such as PTEN and p53. Here, we outline recent developments and discoveries of SUMOylation in PCa and present an overview of its multiple roles in PCa tumorigenesis/promotion and suppression, while elucidating its potential as a therapeutic target for PCa.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据